What is the clinical evidence from this study?

Study design: Other. Population: Healthy subjects (platelet function). Intervention: PEAR1 activation. Primary outcome: Platelet aggregation and signaling pathways.

What question did this study set out to answer?

To delineate the functional signaling role of platelet endothelial aggregation receptor 1 (PEAR1) in human platelet activation and aggregate stabilization.

February 28, 2012Blood

A novel mechanism of sustained platelet αIIbβ3 activation via PEAR1

View Full Paper

Ask AI

Bookmark

Key result

PEAR1 phosphorylation recruits p85 PI3K, leading to persistent PI3K and Akt activation that amplifies αIIbβ3 activation and stabilizes platelet aggregates.

Population

Human platelets

Design

Preclinical

Authors

AKAlexandre KauskotHôpital Necker-Enfants Malades MMMichela Di MicheleCentre National de la Recherche Scientifique SLSerena LoyenKU Leuven

Discussion

Member takes

Implication

May support PEAR1-PI3K targeting for antithrombotic development; leaves open translation from animal models to human platelet disorders.

Key Points

To delineate the functional signaling role of platelet endothelial aggregation receptor 1 (PEAR1) in human platelet activation and aggregate stabilization.
Assessed PEAR1 surface expression and tyrosine phosphorylation in human platelets undergoing agonist-stimulated aggregation.
Treated platelets with recombinant PEAR1 EMI domain constructs, extracellular domain polyclonal antibodies, and F(ab) fragments to modulate aggregation and degranulation.
Characterized downstream signaling interactions with Src family kinases (c-Src, Fyn), PI3K, and Akt in the presence or absence of inhibitors PP1 and LY294002.
Agonist-induced aggregation increased PEAR1 membrane expression and tyrosine phosphorylation, whereas recombinant GST-EMI competitively impaired adhesion, reduced aggregation, and ablated phosphorylation.
Antibody-mediated cross-linking of PEAR1 induced SFK-dependent phosphorylation, leading to extensive degranulation and irreversible platelet aggregation that was blocked by monovalent F(ab) fragments.
Phosphorylated PEAR1 recruited the p85 subunit of PI3K, sustaining downstream Akt activation and amplifying alpha IIb beta 3 activation, a stabilization cascade fully abolished by PP1 and LY294002.

Structured PICO

Population

Human platelets

Intervention

Recombinant PEAR1 EMI domain, polyclonal antibodies against extracellular PEAR1 domain, and kinase inhibitors (PP1, LY294002)

Outcome

Platelet aggregation, PEAR1 phosphorylation, and downstream signaling (PI3K/Akt pathway activation)surrogate

The study identifies PEAR1 as a key regulator of sustained platelet αIIbβ3 activation via the PI3K/Akt pathway, providing a mechanistic basis for its genetic association with platelet function.

Cite This Study

Kauskot et al. (2012) studied Healthy subjects (platelet function). PEAR1 activation was evaluated on Platelet aggregation and signaling pathways. PEAR1 phosphorylation recruits p85 PI3K, leading to persistent PI3K and Akt activation that amplifies αIIbβ3 activation and stabilizes platelet aggregates.

synapsesocial.com/papers/6a96b5efdc355c9d4e89825c https://doi.org/10.1182/blood-2011-11-392787

View Full Paper

Ask AI

Bookmark

A novel mechanism of sustained platelet αIIbβ3 activation via PEAR1

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

A novel mechanism of sustained platelet αIIbβ3 activation via PEAR1

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider